PDZK1IP1 and heart failure: PDE5-inhibitors were also associated with a significant decrease in sPAP and exploratory analyses suggested they might be associated with decreased cardiac-specific hospitalizations in heart failure patient but not in patients with corrected valvulopathy and persistent PH.